Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 6/2000

01.06.2000 | Review Article

Agents in Development for Anxiety Disorders

Current Status and Future Potential

verfasst von: Sean D. Hood, Spilios V. Argyropoulos, Prof. David J. Nutt

Erschienen in: CNS Drugs | Ausgabe 6/2000

Einloggen, um Zugang zu erhalten

Abstract

Benzodiazepines have been used as anxiolytics for many years, despite well described withdrawal effects and drug interactions. Serotonergic antidepressants, which benefit from a favourable adverse effect profile and do not cause dependence, are now established first-line treatments for anxiety disorders. It is apparent, however, that current treatments are not ideal, particularly as they do not always produce a complete recovery. Our growing knowledge of the neurobiology of anxiety disorders, aided by advances in neuroimaging and pharmacological challenges, has led to the development of other potential anxiolytics.
Agents with increased specificity for serotonin receptor subtypes have been developed, with the aim of maximising therapeutic efficacy while minimising adverse effects. Novel anxiolytics, such as neuropeptide agonists and antagonists, γ-aminobutyric acid (GABA)A receptor partial agonists, N-methyl-D-aspartate (NMDA) receptor antagonists, neurosteroids and others, are currently in development and may eventually offer alternatives to currently available agents.
Literatur
1.
American Psychiatric Association. Diagnostic and statisticalmanual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
2.
Regier DA, Boyd JH, Rae DS, et al. One-month prevalenceof mental disorders in the US: based on five epidemiologiccatchment area (ECA) sites. Arch Gen Psychiatry 1988; 45: 977–86PubMedCrossRef
3.
Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry 1998; 59 Suppl. 8: 11–6
4.
Candilis PJ, McLean RY, Otto MW, et al. Quality of life in patients with panic disorder. J Nerv Ment Dis 1999 Jul; 187(7): 429–34PubMedCrossRef
5.
Ballenger JC. Selective serotonin reuptake inhibitors (SSRIs) in panic disorder. Nutt DJ, Ballenger JC, Lepine J-P, editors. Panic disorder. Clinical diagnosis, management and mechanisms. London: Martin Dunitz, 1999: 159–78
6.
Graeff FG, Silveira MC, Nogueira RL, et al. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 1993; 58(1–2): 123–31PubMedCrossRef
7.
Graeff FG, Viana MB, Mora PO. Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 1997; 21(6): 791–9PubMedCrossRef
8.
Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry 1998; 44(12): 1264–76PubMedCrossRef
9.
Reilly JG, McTavish SFB, Young AH. Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. J Psychopharmacology 1997; 11: 381–92CrossRef
10.
Åberg-Wisted A, Hasselmark L, Stain-Malmgren R, et al. Serotonergic ‘vulnerability’ in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. Acta Psychiatr Scand 1998; 97: 374–80CrossRef
11.
Bremner JD, Innis RB, Salomon RM, et al. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 1997; 54, 364–74PubMedCrossRef
12.
Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: reversal of anti-depressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 45, 2323–32
13.
Delgado PL, Price LH, Miller HL, et al. Rapid serotonin depletion as a provocative challenge for patients with major depression: relevance to antidepessant action and the neurobiology of depression. Psychopharmacol Bull 1991; 29: 389–96
14.
Delgado PL, Miller HL, Salomon RM, et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role in the mechanism of antidepressant action. Biol Psychiatry 1999; 46: 212–20PubMedCrossRef
15.
Barr LC, Goodman WK, McDougle CJ, et al. Tryptophan depletionin patients with obsessive-compulsive disorder whorespond to serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51, 309–17PubMedCrossRef
16.
Smeraldi E, Diaferia G, Erzegovesi S, et al. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 1996; 40: 398–402PubMedCrossRef
17.
Rasmusson AM, Anderson GM, Lynch KA, et al. Apreliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette’s syndrome. Biol Psychiatry 1997; 41, 117–21PubMedCrossRef
18.
Nutt D, Forshall S, Bell C, et al. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 1999; 9 Suppl. 3: S81–6PubMedCrossRef
19.
Pecknold JC. Serotonin abnormalities in panic disorder. In: Ballenger JC, editor. Neurobiology of panic disorder. New York (NY): Wiley-Liss, 1990: 121–42
20.
File SE, Hyde JRG. The effects of p-chlorophenylalanine and ethanolamine-O-sulphate in an animal test of anxiety. J Pharmacol 1977; 29: 735–8CrossRef
21.
Graeff NG, Filho NGS. Behavioural inhibition induced by electricalstimulation of the median raphe nucleus of the rat. Physiol Behav 1978; 21: 477–84PubMedCrossRef
22.
Charney DS, Heninger GR. Abnormal regulation of noradrenergicfunction in panic disorders: effects of clonidine in healthysubjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 1986; 43(11): 1042–54PubMedCrossRef
23.
Kahn RS, Westenberg HG, Verhoeven WM, et al. Effect of aserotonin precursor and uptake inhibitor in anxiety disorders;a double-blind comparison of 5-hydroxytryptophan, clomipramineand placebo. Int Clin Psychopharmacol 1987; 2(1): 33–45PubMedCrossRef
24.
Charney DS, Woods SW, Goodman WK, et al. Serotonin functionin anxiety: II. Effects of the serotonin agonist MCPP inpanic disorder patients and healthy subjects. PsychopharmacologyBerl 1987; 92(1): 14–24
25.
Hollander E, DeCaria CM, Nitescu A, et al. Serotonergic functionin obsessive-compulsive disorder: Behavioral and neuroendocrineresponses to oral m-chlorophenylpiperazine andfenfluramine in patients and healthy volunteers. Arch GenPsychiatry 1992 Jan; 49(1): 21–8CrossRef
26.
Eriksson E, Engberg G, Bing O, et al. Effects of mCPP on theextracellular concentrations of serotonin and dopamine in ratbrain. Neuropsychopharmacology 1999; 20(3): 287–96PubMedCrossRef
27.
Germine M, Goddard AW, Sholomskas DE, et al. Response tometa-chlorophenylpiperazine in panic disorder patients andhealthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 1994; 54(2): 115–33PubMedCrossRef
28.
Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry 1998; 173 Suppl. 35: 64–70
29.
Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsivedisorder. Depress Anxiety 1998; 8 Suppl. 1: 105–13CrossRef
30.
Blier P, de Montigny C. Possible serotonergic mechanisms underlyingthe antidepressant and anti-obsessive-compulsive disorderresponses. Biol Psychiatry 1998 Sep 1; 44(5): 313–23PubMedCrossRef
31.
Rickels K, Schweizer E, De Martinis M, et al. Gepirone anddiazepam in generalised anxiety disorders: a placebo-controlledtrial. J Clin Psychopharmacol 1997; 17: 272–7PubMedCrossRef
32.
Pecknold JC, Luthe L, Scott Fleury MH, et al. Gepirone and thetreatment of panic disorder: an open study. J Clin Psychopharmacol 1993; 13(2): 145–9PubMedCrossRef
33.
Berenyi E, Blasko G, Fekete M, et al. EGYT-3886. Drugs Future 1990 Dec; 15: 1174–5
34.
Detari L, Szentgyorgyi V, Hajnik T, et al. Differential EEGeffects of the anxiolytic drugs, deramciclane (EGIS-3886),ritanserin and chlordiazepoxide in rats. PsychopharmacologyBerl 1999 Mar; 142(3): 318–26CrossRef
35.
Freeman AM, Westphal JR, Norris GT, et al. The efficacy of ondansetron in the treatment of generalised anxiety disorder. Depress Anxiety 1997; 5: 140–1PubMedCrossRef
36.
Depot M, Merani S, Bradwejn J, et al. Effect of oral ondansetronon total cholecystokinin plasma levels following CCK-4panic challenge procedure in healthy men. J Psychiatry Neurosci 1998; 23(5): 298–304PubMed
37.
Schneier FR, Garfinkel R, Kennedy B, et al. Ondansetron in thetreatment of panic disorder. Anxiety 1996; 2(4): 199–202PubMedCrossRef
38.
Bell J, DeVeaugh-Geiss J. Multicenter trial of a 5-HT3 antagonist,ondansetron in social phobia [poster]. Presented at the33rd Annual Meeting of the American College of Neuropsychopharmacology; 1994 Dec 12–16; San Juan, Puerto Rico
39.
Smith WT, Londborg PD, Blomgren SL, et al. Pilot study ofzotosetron (LY277359) maleate, a 5-hydroxytryptamine-3antagonist, in the treatment of anxiety. J Clin Psychopharmacol 1999 Apr; 19: 125–31PubMedCrossRef
40.
Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressantsin the treatment of PTSD. Depress Anxiety 1997;5: 137–9PubMedCrossRef
41.
van Vliet IM, Westenberg HGM, den Boer JA. Effects of the5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology 1996 Sep; 127: 174–80PubMedCrossRef
42.
Deren-Wesolek A, Tatarcznska E, Chojnacka-Wojcik E. Thenovel buspirone analogue, 8- [4- [2- (1,2,3,4-tetrahydroisoquinolinyl)[butyl] -8-azaspiro [4.5] decane-7,9-dione, withanxiolytic-like and antidepressant-like effects in rats. J Psychopharmacol 1998; 12(4): 380–4PubMedCrossRef
43.
Hanes KR. Serotonin, psilocybin, and body dysmorphic disorder:a case report. J Clin Psychopharmacol 1996; 16: 188–9PubMedCrossRef
44.
Baumgarten HG, Grozdanovic Z. Role of serotonin in obsessive-compulsivedisorder. Br J Psychiatry Suppl 1998; 35: 13–20PubMed
45.
McDougle CJ, Goodman WK, Price LH. Dopamine antagonistsin tic related and psychotic spectrum obsessive compulsivedisorder. J Clin Psychiatry 1994; 55 Suppl. 3: 24–31
46.
Koran L, Ringold A, Elliott M. Olanzapine added to fluoxetinein unresponsive obsessive-compulsive disorder [abstract 3.020].Eur Neuropsychopharmacol 1999; 9 Suppl. 5: S305
47.
O’Hanlon JF, Robbe HW, Verneeren A, et al. Venlafaxine’s effectson healthy volunteers’ driving, psychomotor, and vigilanceperformance during 15-day fixed and incrementaldosing regimens. J Clin Psychopharmacol 1998 Jun; 18(3): 221–21
48.
American Home Products Corporation. American Home Products announces Effexor (R) XR receives FDA approval for the treatment of generalized anxiety disorder. Media Release. 1999 Mar 12; 3 pages
49.
Wyeth-Ayerst Laboratories. New studies demonstrate long-termeffectiveness of Effexor (R) XR in treating symptoms of generalisedanxiety disorder. Media Release. 1999 Mar 26; 2 pages
50.
Hackett D, Haudiquet V, Salinas E. A dose-response, 6 monthevaluation of venlafaxine extended-release in outpatients withgeneralized anxiety disorder [abstract]. The Summer Meetingof the British Association for Psychopharmacology; 1999 Jul25; J Psychopharmacol 1999; 13(3): A44
51.
Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995; 31(4): 767–71PubMed
52.
Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia:a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999 Jul; 14(4): 239–45PubMedCrossRef
53.
Koran L, Quirk T, Lorberbaum J. Mirtazepine treatment ofobsessive-compulsive disorder [abstract P.3.022]. Eur Neuropsychopharmacol1999; 9 Suppl. 5: S305–S306
54.
Longhurst JG, Carpenter LL, Epperson CN, et al. Effects ofcatecholamine depletion with AMPT (alpha-methyl-paratyrosine)in obsessive-compulsive disorder. Biol Psychiatry 1999 Aug 15; 46(4): 573–6PubMedCrossRef
55.
Braestrup C, Squires RF. Brain specific benzodiazepine receptors. Br J Psychiatry 1978 Sep; 133: 249–60PubMedCrossRef
56.
Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999 Apr; 29(2–3): 196–217PubMedCrossRef
57.
Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature 1999 Oct 21; 401: 796–800PubMedCrossRef
58.
Pincock C, Jensen NO, Oliver S, et al. Cognitive effects of multiple doses of ME3127, a novel anxiolytic, in volunteers[abstract P71]. J Psychopharmacol 1999; 13(3 Suppl. A): A27
59.
Jones S, Jensen NO, Oliver S, et al. Cognitive effects of singledoses of ME3127, a novel anxiolytic, in volunteers [abstractP70]. J Psychopharmacol 1999; 13(3 Suppl. A): A27
60.
Linden M, Hadler D, Hofmann S. Randomised, double-blind, placebo-controlled trial of the efficacy and tolerability of anew isoindoline derivative (DN-2327) in generalized anxiety. Hum Psychopharmacol Clin Exper 1997 Sep; 12: 445–52CrossRef
61.
Evans SM, Fukuda N, Levin FR, et al. Behavioral and subjectiveeffects of DN-2327 (pazinaclone) and alprazolam in normalvolunteers. Behav Pharmacol 1995 Mar; 6: 176–86PubMedCrossRef
62.
Suzuki M, Uchiumi M, Murasaki M. Acomparative study of thepsychological effects of DN-2327, a partial benzodiazepineagonist, and alprazolam. Psychopharmacology 1995 Oct; 121(4): 442–50PubMedCrossRef
63.
Interneuron Pharmaceuticals Inc. Interneuron’s pagoclone significantlyreduces panic attacks in phase 2/3 clinical trial.Media Release. 1998 Aug 17; 2 pages
64.
Interneuron Pharmaceuticals Inc. Interneuron’s announces positivephase 2 data on pagoclone in panic disorders. Media Release. 1997 Nov 20; 2 pages
65.
Tang AH, Franklin SR, Carter DB, et al. Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor.Psychopharmacology 1997 Jun; 131: 255–63PubMedCrossRef
66.
Mumford GK, Rush CR, Griffiths RR. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exper Ther 1995 Feb; 272: 570–80
67.
Aufdembrinke B. Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. Br J Psychiatry 1998 Jul; 173 Suppl. 34: 63
68.
Argyropoulos S, Nutt D. Peptide receptors as targets for anxiolyticdrugs. In: Briley M, Nutt D, editors. Milestones in drug therapy: anxiolytics. Basel: Birkhauser Verlag, 2000. In press
69.
Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism forantidepressant activity by blockade of central substance P receptors[see comments]. Science 1998 Sep 11; 281(5383):1640–5PubMedCrossRef
70.
Adams JB, Pyke RE, Costa J, et al. A double-blind, placebo-controlledstudy of a CCK-B receptor antagonist, CI-988, inpatients with generalized anxiety disorder. J Clin Psychopharmacol 1995 Dec; 15(6): 428–34PubMedCrossRef
71.
Goddard AW, Woods SW, Money R, et al. Effects of the CCK(B)antagonist CI-988 on responses to mCPP in generalized anxietydisorder. Psychiatry Res 1999 Mar 22; 85(3): 225–40PubMedCrossRef
72.
van Megen HJ, Westenberg HG, den Boer JA, et al. The cholecystokinin-Breceptor antagonist CI-988 failed to affect CCK-4induced symptoms in panic disorder patients. PsychopharmacolBerl 1997 Feb; 129(3): 243–8CrossRef
73.
Hasenohrl RU, Jentjens O, De Souza-Silva MA, et al. Anxiolytic-likeaction of neurokinin substance P administered systemically or into the nucleus basalis magnocellularis region.Eur J Pharmacol 1998 Aug 7; 354(2–3): 123–33PubMedCrossRef
74.
Nutt D. Substance-P antagonists: a new treatment for depression?Lancet 1998 Nov 21; 352: 1644–5PubMedCrossRef
75.
Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther 1999 Apr;82(1): 1–61PubMedCrossRef
76.
de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings [see comments]. Arch Gen Psychiatry 1989 Jun; 46(6): 511–7PubMedCrossRef
77.
van Megen HJ, Westenberg HG, den Boer JA, et al. The panic-inducing properties of the cholecystokinin tetrapeptide CCK4in patients with panic disorder. Eur Neuropsychopharmacol 1996; 6(3): 187–94PubMedCrossRef
78.
Brawman Mintzer O, Lydiard RB, Bradwejn J, et al. Effects ofthe cholecystokinin agonist pentagastrin in patients with generalizedanxiety disorder. Am J Psychiatry 1997; 154(5): 700–2PubMed
79.
De Leeuw AS, den Boer JA, Slaap BR, et al. Pentagastrin haspanic-inducing properties in obsessive compulsive disorder. Psychopharmacol Berl 1996; 126(4): 339–44CrossRef
80.
van Vliet IM, Westenberg HG, Slaap BR, et al. Anxiogeniceffects of pentagastrin in patients with social phobia and healthycontrols. Biol Psychiatry 1997; 42(1): 76–8PubMedCrossRef
81.
van Megen HJ, Westenberg HG, den Boer JA, et al. Effect ofthe selective serotonin reuptake inhibitor fluvoxamine on CCK-4induced panic attacks. Psychopharmacol Berl 1997; 129(4):357–64CrossRef
82.
van Megen HJ, Westenberg HG, den Boer JA, et al. Cholecystokininin anxiety. Eur Neuropsychopharmacol 1996; 6(4):263–80PubMedCrossRef
83.
Becker C, Hamon M, Benoliel JJ. Prevention by 5-HT1A receptoragonists of restraint stress- and yohimbine-induced releaseof cholecystokinin in the frontal cortex of the freelymoving rat. Neuropharmacology 1999 Apr; 38(4): 525–32PubMedCrossRef
84.
Gewirtz JC, Davis M. Beyond attention: the role of amygdalaNMDA receptors in fear conditioning [commentary]. BehavBrain Sci 1997 Dec; 20(4): 618
85.
Lensi P, Cassano GB, Correddu G, et al. Obsessive-compulsivedisorder: familial-developmental history, symptomatology, comorbidityand course with special reference to gender-relateddifferences. Br J Psychiatry 1996; 169(1): 101–7PubMedCrossRef
86.
Kunovac JL, Stahl SM. Future directions in anxiolytic pharmacotherapy. Psychiatr Clin North Am 1995 Dec; 18(4): 895–909PubMed
87.
Liebsch G, Landgraf R, Engelmann M, et al. Differential behaviouraleffects of chronic infusion of CRH 1 and CRH 2receptor antisense oligonucleotides into the rat brain. J PsychiatrRes 1999 Mar; 33(2): 153–63
88.
Rasmusson AM, Southwick SM, Hauger RL, et al. Plasma neuropeptideY (NPY) increases in humans in response to thealpha 2 antagonist yohimbine. Neuropsychopharmacology 1998; 19(1): 95–8PubMedCrossRef
89.
Grundemar L, Håkanson R. Neuropeptide Y effector systems:perspectives for drug development. Trends Pharmacol Sci 1994May; 15(5): 153–9PubMedCrossRef
90.
Stein MB, Hauger RL, Dhalla KS, et al. Plasma neuropeptideY in anxiety disorders: findings in panic disorder and socialphobia. Psychiatry Res 1996; 59(3): 183–8PubMedCrossRef
91.
Boulenger JP, Jerabek I, Jolicoeur FB, et al. Elevated plasmalevels of neuropeptide Y in patients with panic disorder. AmJ Psychiatry 1996; 53(1): 114–6
92.
Adamec RE, Burton P, Shallow T, et al. Unilateral block ofNMDA receptors in the amygdala prevents predator stress-inducedlasting increases in anxiety-like behavior and unconditionedstartle: effective hemisphere depends on the behavior.Physiol Behav 1999 Jan 1; 65(4–5): 739–51PubMed
93.
Cratty MS, Birkle DL. N-methyl-D-aspartate (NMDA)-mediatedcorticotropin-releasing factor (CRF) release in culturedrat amygdala neurons. Peptides 1999; 20(1): 93–100PubMedCrossRef
94.
Adamec RE, Burton P, Shallow T, et al. NMDA receptors mediatelasting increases in anxiety-like behavior produced bythe stress of predator exposure: implications for anxiety associatedwith posttraumatic stress disorder. Physiol Behav1999 Jan 1; 65(4–5): 723–37PubMed
95.
Parsons CG, Danysz W, Quack G. Memantine is a clinicallywell tolerated N-methyl-D-aspartate (NMDA) receptor antagonist:a review of preclinical data. Neuropharmacology 1999 Jun; 38(6): 735–67PubMedCrossRef
96.
Gasior M, Carter RB, Witkin JM. Neuroactive steroids: potentialtherapeutic use in neurological and psychiatric disorders.Trends Pharmacol Sci 1999 Mar; 20(3): 107–12PubMedCrossRef
97.
Rupprecht R, Holsboer F. Neuropsychopharmacological propertiesof neuroactive steroids. Steroids 1999 Jan; 64(1–2):83–91PubMedCrossRef
98.
Frye CA, Lacey EH. The neurosteroids DHEA and DHEASmay influence cognitive performance by altering affectivestate. Physiol Behav 1999 Mar; 66(1): 85–92PubMedCrossRef
99.
Pande AC, Davidson JRT, Jefferson JW, et al. Treatment ofsocial phobia with gabapentin: a placebo-controlled study. JClin Psychopharmacol 1999; 19(4): 341–8CrossRef
100.
Benjamin J, Levine J, Fux M, et al. Inositol treatment for panicdisorder: a double-blind placebo-controlled crossover trial. Am J Psychiatry 1995; 152: 1084–6PubMed
101.
Fux M, Levin FR, Aviv A, et al. Inositol treatment of obsessive-compulsivedisorder. Am J Psychiatry 1996; 153: 1219–21PubMed
102.
de Paris F, Busnello JV, Vianna MRM, et al. Gabapentin presentsanxiolytic but not amnestic effects in rats [abstract P105].J Psychopharmacol 1999; 13(3 Suppl. A): A36
103.
Kaplan Z, Amir M, Swartz M, et al. Inositol treatment of posttraumaticstress disorder. Anxiety 1996; 2: 51–2PubMedCrossRef
104.
Walkup J, Reeve E, Yaruyura-Tobias J, et al. Fluvoxamine inchildhood OCD: long-term treatment [abstract P.3.025]. EurNeuropsychopharmacol 1999; 9 Suppl. 5: S307CrossRef
Metadaten
Titel
Agents in Development for Anxiety Disorders
Current Status and Future Potential
verfasst von
Sean D. Hood
Spilios V. Argyropoulos
Prof. David J. Nutt
Publikationsdatum
01.06.2000
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 6/2000
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200013060-00004

Weitere Artikel der Ausgabe 6/2000

CNS Drugs 6/2000 Zur Ausgabe

Leading Article

Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors

Review Article

Role of Newer Atypical Antipsychotics in the Management of Treatment-Resistant Schizophrenia

Review Article

Atypical Antipsychotics in the Treatment of Bipolar Disorder

Adis Drug Evaluation

Metrifonate

Disease Management

Epidemiology, Pathophysiology and Treatment of Pathological Gambling

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise